The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Validation of RECIST 1.1 for use with cytotoxic agents and targeted cancer agents (TCA): Results of a RECIST Working Group analysis of a 50 clinical trials pooled individual patient database.
 
Saskia Litière
Research Funding - Abbvie (Inst); AstraZeneca (Inst); Azanta (Inst); Bayer Health (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Eisai (Inst); Ferring (Inst); GlaxoSmithKline (Inst); ImmunoCellular Therapeutics (Inst); Inovio Pharmaceuticals (Inst); Janssen (Inst); Janssen/Cilag (Inst); Merck (Inst); Millennium (Inst); Modra Pharmaceuticals (Inst); MSD (Inst); Novartis (Inst); PharmaMar (Inst); Roche (Inst)
 
Gaëlle Isaac
Research Funding - Several pharmaceutical companies (Inst)
 
Elisabeth De Vries
Consulting or Advisory Role - Medivation (Inst); Merck (Inst); Synthon (Inst)
Research Funding - Amgen (Inst); AstraZeneca (Inst); Chugai Pharma (Inst); CytomX Therapeutics (Inst); Nordic Nanovector (Inst); Novartis (Inst); Radius Health (Inst); Roche/Genentech (Inst); SERVIER (Inst); Synthon (Inst)
Travel, Accommodations, Expenses - Merck
 
Jan Bogaerts
No Relationships to Disclose
 
Alice P. Chen
No Relationships to Disclose
 
Janet Dancey
Research Funding - AstraZeneca/MedImmune (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst)
 
Robert Ford
Consulting or Advisory Role - Radiant Sage; Abbvie; ACR Image Metrix; Amgen; Aptiv Solutions; Aragon Pharmaceuticals; BioClinica; BioMedical Systems; Bristol-Myers Squibb; Celldex; Celsion; cinven; Clovis Oncology; Covance; Eisai; EMD Serono; Exelis; Genentech; ICON Clinical Research; Imaging Endpoints; Janssen; Kyowa Hakko Kirin; Loxo; Merck; Mirati Therapeutics; Novartis; Novocure; Ono Pharmaceutical; OrbiMed; Pfizer; Quintiles; RedHill Biopharma; Roche; Tokai Pharmaceuticals; Virtual Scopis
Travel, Accommodations, Expenses - Pharmaceutical Education and Research Institute
 
Steve J Gwyther
Employment - Celgene (I)
Stock and Other Ownership Interests - Lilly (I)
Travel, Accommodations, Expenses - Celgene (I)
 
Otto S. Hoekstra
No Relationships to Disclose
 
Erich Huang
No Relationships to Disclose
 
Nancy U Lin
No Relationships to Disclose
 
Yan Liu
No Relationships to Disclose
 
Sumithra J. Mandrekar
Consulting or Advisory Role - Pfizer; Pique
Other Relationship - Beigene
 
Lawrence HOWARD SCHWARTZ
Consulting or Advisory Role - GlaxoSmithKline; Novartis
Research Funding - Astellas Pharma (Inst); Lilly (Inst); Merck Sharp & Dohme (Inst); Pfizer (Inst)
Patents, Royalties, Other Intellectual Property - Varian Medical Systems
 
Lalitha Shankar
No Relationships to Disclose
 
Patrick Therasse
Employment - SERVIER
Stock and Other Ownership Interests - GlaxoSmithKline
 
Lesley Seymour
Stock and Other Ownership Interests - AstraZeneca
Consulting or Advisory Role - Boehringer Ingelheim
Research Funding - AstraZeneca (Inst); Innate Pharma (Inst); Merck (Inst); Oncolytics (Inst); Pfizer (Inst)